Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23664863 | 0.85 | P2RX7 (0.35) | MEN1KMT2AP2RX7NR1H2NR1H3 | |
| SCHEMBL6193205 | 0.83 | CA2 (0.44) | MEN1KMT2ASLC22A12TAS2R14HSD11B1 | |
| SCHEMBL30821286 | 0.83 | CA2 (0.44) | MEN1KMT2ASLC22A12TAS2R14HSD11B1 | |
| SCHEMBL22489744 | 0.83 | TRPV4 (0.42) | MEN1KMT2AP2RX7SLC22A12TAS2R14 | |
| SCHEMBL515098 | 0.82 | KMT2A (0.56) | MEN1KMT2ASLC22A12HSD11B1 | |
| SCHEMBL23665026 | 0.79 | MEN1 (0.42) | MEN1KMT2AP2RX7NR1H2NR1H3 | |
| SCHEMBL11217498 | 0.79 | NR1H2 (0.43) | MEN1KMT2AP2RX7NR1H2NR1H3 | |
| SCHEMBL27841267 | 0.79 | HSD11B1 (0.52) | MEN1KMT2ASLC22A12TAS2R14HSD11B1 | |
| SCHEMBL4781258 | 0.76 | SLC22A12 (0.41) | MEN1KMT2ASLC22A12TAS2R14 | |
| SCHEMBL6630838 | 0.76 | TAS2R14 (0.46) | P2RX7TAS2R14HSD11B1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-15 | — | — | US | disclosed |
| EP-4448513-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BeiGene Switzerland GmbH (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401514-A | 3, 4-Dihydroisoquinolin-1 (2H) -one derivatives as STING antagonists and uses thereof | 百济神州有限公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2023109912-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109912-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022135591-A1 | ARYL OR HETEROARYL PYRIDONE OR PYRIMIDONE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2021249563-A1 | ARYL OR HETEROARYL PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | STING1, IRF3, MAVS | MEN1 3424/4885KMT2A 3703/4885P2RX7 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.